Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1185-1189

  Gladieff, L ^a   Ferrero, A ^b   De rauglaudre, G ^c   Brown, C ^d   Vasey, P ^e   Reinthaller, A ^f   Pujade Lauraine, E ^g   Reed, N ^h   Lorusso, D ⁱ   Siena, S ^j   Helland, H ^k   Elit, L ^l   Mahner, S ^m  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b MAURIZIANO HOSPITAL   (Italy)

^c INSTITUT SAINTE CATHERINE   (France)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY OF VIENNA   (Austria)

^g HÔTEL DIEU   (France)

^h GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^l JURAVINSKI CANCER CENTRE   (Canada)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

CALYPSO; Carboplatin; Ovarian cancer; Paclitaxel; Partially platinum sensitive; Pegylated liposomal doxorubicin

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 84860470644     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr441     Document Type: Article

References (18)

1. Pujade-Lauraine E, Paraiso D, Cure H et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002; 21: (Abstr 829).
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Ovarian cancer. v.1.2011. 2010;; http://www.nccn.org/professionals/ physician_gls/PDF/ovarian.pdf. (19 October 2010, date last accessed).
3. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-653.
4. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
5. Gordon A, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
6. Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263-268.
7. Weber B, Lortholary A, Mayer F et al. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res 2009; 29: 4195-4200.
8. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329.
9. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361(9375): 2099-2106.
10. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24(29): 4699-4707.
11. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28(19): 3107-3114.
12. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxrubicin in relapsed ovarian cancer: outcomes in the partially platinumsensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22(1): 39-48.
13. Bertelsen K, Jakobsen I, Nielsen SK et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DA-COVA). Gynecol Oncol 1993; 49: 30-36.
14. Lambert HE, Rustin GJ, Gregory WM et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: A North Thames Ovary Group Study. Ann Oncol 1997; 8: 327-333.
15. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005; 15 (Suppl 1): 3-11.
16. Rapoport BL, Vorobiof DA, Slabber C et al. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 2009; 19: 1137-1141.
17. Markman M, Moon J, Wilczynski S et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 2010; 116: 323-325.
18. Power P, Stuart G, Oza A et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study. Gynecol Oncol 2009; 114: 410-414.